ROIV and ROIVW Related Headlines
Go Back- FDA approves Roivant's brepocitinib pill for dermatomyositis
- Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
- FDA approves Priovant's brepocitinib for dermatomyositis
- Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
- JAMA Dermatology publishes brepocitinib skin data from VALOR trial
- JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
- Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
- Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
ROIV and ROIVW Related Press Releases
Go Back- Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
- Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
- JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
- Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
- Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
